Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.

PURPOSE Acquired somatic uniparental disomy (UPD) is commonly observed in myelodysplastic syndromes (MDS), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), or secondary acute myelogenous leukemia (sAML) and may point toward genes harboring mutations. Recurrent UPD11q led to identification of homozygous mutations in c-Cbl, an E3 ubiquitin ligase involved in attenuation of proliferative signals transduced by activated receptor tyrosine kinases. We examined the role and frequency of Cbl gene family mutations in MPN and related conditions. METHODS We applied high-density SNP-A karyotyping to identify loss of heterozygosity of 11q in 442 patients with MDS, MDS/MPN, MPN, sAML evolved from these conditions, and primary AML. We sequenced c-Cbl, Cbl-b, and Cbl-c in patients with or without corresponding UPD or deletions and correlated mutational status with clinical features and outcomes. RESULTS We identified c-Cbl mutations in 5% and 9% of patients with chronic myelomonocytic leukemia (CMML) and sAML, and also in CML blast crisis and juvenile myelomonocytic leukemia (JMML). Most mutations were homozygous and affected c-Cbl; mutations in Cbl-b were also found in patients with similar clinical features. Patients with Cbl family mutations showed poor prognosis, with a median survival of 5 months. Pathomorphologic features included monocytosis, monocytoid blasts, aberrant expression of phosphoSTAT5, and c-kit overexpression. Serial studies showed acquisition of c-Cbl mutations during malignant evolution. CONCLUSION Mutations in the Cbl family RING finger domain or linker sequence constitute important pathogenic lesions associated with not only preleukemic CMML, JMML, and other MPN, but also progression to AML, suggesting that impairment of degradation of activated tyrosine kinases constitutes an important cancer mechanism.

[1]  J. Maciejewski,et al.  UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation , 2009, Leukemia.

[2]  M. McDevitt,et al.  250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. , 2008, Cancer research.

[3]  B. Löwenberg,et al.  Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias , 2008, Haematologica.

[4]  P. Aplan,et al.  Leukemic transformation in mice expressing a NUP98-HOXD13 transgene is accompanied by spontaneous mutations in Nras, Kras, and Cbl. , 2008, Blood.

[5]  G. Mufti,et al.  Whole genome scanning as a cytogenetic tool in hematologic malignancies. , 2008, Blood.

[6]  K. Mrózek,et al.  Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. , 2008, Seminars in oncology.

[7]  T. Haferlach,et al.  Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype , 2008, Leukemia.

[8]  Axel Benner,et al.  Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.

[9]  C. O'keefe,et al.  Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. , 2008, Blood.

[10]  N. Shinton WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .

[11]  M. McDevitt,et al.  SNP Array Karyotyping Allows for the Detection of Uniparental Disomy and Cryptic Chromosomal Abnormalities in MDS/MPD-U and MPD , 2007, PloS one.

[12]  G. Mufti,et al.  Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. , 2007, Blood.

[13]  C. O'keefe,et al.  Single nucleotide polymorphism arrays complement metaphase cytogenetics in detection of new chromosomal lesions in MDS , 2007, Leukemia.

[14]  M. Caligiuri,et al.  Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. , 2007, Blood.

[15]  Chunaram Choudhary,et al.  Flt3-dependent transformation by inactivating c-Cbl mutations in AML. , 2007, Blood.

[16]  J. Maciejewski,et al.  Bone Marrow Phospho-STAT5 Expression in Non-CML Chronic Myeloproliferative Disorders Correlates With JAK2 V617F Mutation and Provides Evidence of In Vivo JAK2 Activation , 2007, The American journal of surgical pathology.

[17]  A. Tsygankov,et al.  The Cbl family proteins: Ring leaders in regulation of cell signaling , 2006, Journal of cellular physiology.

[18]  J. Maciejewski,et al.  Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. , 2006, Blood.

[19]  Sandra A. Moore,et al.  MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.

[20]  W. Hiddemann,et al.  1 KIT-D 816 mutations in AML 1-ETO positive AML are associated with impaired event-free and overall survival , 2005 .

[21]  S. Fröhling,et al.  Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. , 2006, Blood.

[22]  Ivan Dikic,et al.  The Cbl interactome and its functions , 2005, Nature Reviews Molecular Cell Biology.

[23]  Pawel Stankiewicz,et al.  Genomic Disorders: Molecular Mechanisms for Rearrangements and Conveyed Phenotypes , 2005, PLoS genetics.

[24]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[25]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[26]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[27]  L. Feuk,et al.  Detection of large-scale variation in the human genome , 2004, Nature Genetics.

[28]  D. Bowtell,et al.  Tissue Hyperplasia and Enhanced T-Cell Signalling via ZAP-70 in c-Cbl-Deficient Mice , 1998, Molecular and Cellular Biology.

[29]  W. Langdon,et al.  The sequences of the human and mouse c-cbl proto-oncogenes show v-cbl was generated by a large truncation encompassing a proline-rich domain and a leucine zipper-like motif. , 1991, Oncogene.

[30]  D. Gilliland Hematologic malignancies. , 2001, Current opinion in hematology.